MB Immunotherapy Program

Medulloblastoma Immunotherapy Overview

VBI has applied its eVLP Platform in the development of a medulloblastoma (“MB”) therapeutic vaccine candidate. With its novel approach, VBI intends to create a MB immunotherapy that will stimulate the patient’s own immune system to identify and attack MB tumor cells, while sparing the vulnerable surrounding brain that is still developing in children.

The Meghan Rose Bradley Foundation, a pediatric brain cancer advocacy organization, provided a grant to fund initial research in ex vivo studies. VBI is evaluating the ability of its MB immunotherapy to stimulate CD4+ and CD8+ T cell responses in peripheral blood mononuclear cells (“PBMCs”) harvested from healthy patients and patients with medulloblastoma; CD4+ and CD8+ immune responses are critical to efficacious anti-tumor immunity. VBI will also monitor several biomarkers predictive of clinical efficacy.

CT scan of a six year old girl showing a MB tumorous mass in the posterior fossa, giving rise to obstructive hydrocephalus.

About Medulloblastoma
VBI-1901 Design

MB Medical Need and Its Relationship to Cytomegalovirus

Medulloblastoma is the most common malignant primary brain tumor in children.1 Standard of care treatment consists of surgical removal of the tumor followed by chemotherapy and radiation, depending on the patient’s staging and age.2 Radiation therapy is rarely administered to children under three years of age because of the high potential for serious neurodevelopmental deficits, further limiting the treatment options available to the youngest patients.3 While modern treatments have led to improvements in survival, the risk of recurrence as well as the long-term side effects associated with surgery, radiation, and chemotherapy underscore the urgent need for new therapeutic approaches.4

Developing a medulloblastoma immunotherapy requires the identification of antigens, used to direct the immune response, that are consistently expressed on tumor cells. Recent research has demonstrated that medulloblastoma tumors are particularly susceptible to infection by cytomegalovirus (“CMV”), with over 90% of some medulloblastoma tumors expressing CMV antigens.5 In addition, antiviral therapies that inhibit CMV replication have been shown to reduce medulloblastoma tumor cell growth, both in vitro and in vivo, suggesting that CMV may increase the malignancy of infected cells.6

Medulloblastoma Resources

MB Candidate Design and Manufacture

VBI is leveraging its eVLP Platform and its expertise in anti-CMV immunity to develop a polyvalent therapeutic vaccine candidate designed to direct an immune response against gB and pp65, two CMV antigens that are highly immunogenic targets during natural infection. The vaccine candidate includes granulocyte-macrophage colony-stimulating factor (“GM-CSF”), an adjuvant that mobilizes dendritic function and enhances Th1-type immunity.7


Pilot (10L) scale production of VBI’s vaccine candidate is now underway at a GMP-compliant facility. During recent testing, VBI employed electron microscopy to confirm the integrity of the polyvalent eVLPs, with positive interim results.6 Purity measurements are expected to meet regulatory requirements for clinical evaluation of the vaccine candidate.

eVLP Target Prophylactic CMV Vaccine Therapeutic Immuno-Oncology Vaccine
Antigen(s) gB gB and pp65
Antigen in Natural Conformation +++ +++
Broadly Reactive Neutralizing Antibodies +++ +++
Polyvalent Immune response ++
Potent Th1 Cellular Immunity for Therapeutic Applications CD4+ ++ +++
CD8+ ++

Recent Medulloblastoma Program News and Insights